Wells Fargo Maintains Overweight on Bio-Techne, Lowers Price Target to $62

Benzinga Newsdesk www.benzinga.com Negative 84.7%

Neg 84.7% Neu 0% Pos 0%

Wells Fargo analyst Brandon Couillard maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $76 to $62.